Celerion
Belfast, Northern Ireland, BT9 6AD, United Kingdom
NCT Number: NCT04451811
This is a single center, randomized, open-label, three-way crossover, single dose, pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Belfast, Northern Ireland, BT9 6AD, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Spray dried dispersion and tablet formulation
Time frame: 0 to 48 hours
Time frame: 0 to 48 hours
Time frame: 0 to 48 hours
Oppilan Pharma Ltd
Industry
A Pharmacokinetic Dose Proportionality Study of OPL-002 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details